Biocept

Biocept SGA/Revenue

Delisted

The SGA to Revenue Ratio of Biocept (BIOC) as of Nov 3, 2026 is 62.31 %. In the previous year, SGA to Revenue Ratio was 20.59 % — a change of 202.57% (higher).

SGA/Revenue

62.31 %

YoY

202.57%

Last updated:

SGA to Revenue Ratio of Biocept is 2022 62.31 % . SGA to Revenue Ratio of Biocept was 2021 20.59 % . It decreases by 202.57% higher compared to the previous year.

The Biocept SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2015
932.34 USD
Jan 1, 2016
203.54 USD
Jan 1, 2017
141.84 USD
Jan 1, 2018
217.64 USD
Jan 1, 2019
126.07 USD
Jan 1, 2020
36.32 USD
Jan 1, 2021
20.59 USD
Jan 1, 2022
62.31 USD
The Biocept SGA/Revenue history
YEARSGA/RevenueYoY
62.31 %+202.57%
20.59 %-43.29%
36.32 %-71.19%
126.07 %-42.07%
217.64 %+53.44%
141.84 %-30.31%
203.54 %-78.17%
932.34 %-76.09%
3,899.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

SGA to Revenue Ratio of Biocept is 62.31 % in 2022.

SGA to Revenue Ratio of Biocept changed from 20.59 % to 62.31 %, representing a 202.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Biocept since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Biocept with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biocept

All Key Metrics — Biocept